Skip to main content

Childhood Sexual Abuse Alters Female Brain Structure


April 19, 2012 (Arlington, Virginia) — Women with a history of childhood sexual abuse have changes in brain structure that may relate to genital sensation, a new imaging study shows.
Presented here at the Anxiety Disorders Association of America (ADAA) 32nd Annual Conference, investigators from the University of Miami in Florida found that early life trauma was related to much thinner somatosensory cortex, smaller hippocampal volume, and neurocognitive deficits.
"Is it possible that the somatic representation of the cortex for the genital area might actually be changed in women with [a history of] sexual abuse? It's a pretty far-out thought," principal investigator Charles Nemeroff, MD, from the University of Miami told conference delegates.
The study included 56 women aged 18 to 45 years with current major depression and either with or without a history of childhood sexual abuse, assessed by the Childhood Trauma Questionnaire.
Using standard cortical thickness analysis measures, investigators found a "marked reduction in the somatosensory cortical thickness area for the genital region in women with sexual abuse — the results were really quite significant," said Dr. Nemeroff.
The findings correspond with earlier work published by Dr. Nemeroff and colleagues showing that depressed women with a history of childhood abuse had an 18% smaller mean left hippocampal volume than nonabused depressed women (Am J Psychiatry, 2002;159:2072-80).
Uphill Battle
Expanding on that work, the investigators have also just published findings showing that early life trauma in general, including physical or sexual abuse or neglect, in both men and women is associated with neurocognitive deficits compared with control participants — with sexual abuse associated with signature deficits in visual working memory and executive functioning (J Psychiatr Res, 2012;4:500-6).
"We could actually, remarkably...separate out pretty clearly the neuropsychological profiles of the normal volunteers, the patients with neglect, and the patients with abuse, and the patients with abuse and neglect. It is really quite interesting," he said.
Taken together, the findings add neuroimaging and neuropsychological pieces to the psychiatric puzzle of the long-term effects of early life trauma in adult mood and anxiety disorders, said Dr. Nemeroff.
"The developing brain is vulnerable to insult," he said. "The human brain is not mature until age 23. It became clear to me that a great many patients with mood and anxiety disorders had early trauma histories, and they seemed to me to not respond as well to the conventional treatments as did other patients. This is really an uphill battle."
Dr. Nemeroff's early work with rodents and primates deprived of maternal contact showed an abnormal pituitary and adrenal response to stress that was subsequently confirmed in humans. This finding suggests that early life trauma sensitizes the nervous system and maintains it in a heightened state, he explained.
Asked by a conference attendee whether the thinner genital somatosensory cortex found in women with a history of abuse could be the result of decreased sexual activity as a result of abuse rather than the abuse itself, Dr. Nemeroff said that these women are not necessarily less sexually active than nonabused women.
However, he added, "they certainly show anhedonia in relation to sexual activity, and the cohort of patients with early life trauma also have much higher rates of adult trauma as well — so there's not enough information to answer that question."
Reversible?
"The question is how plastic is it? Can we reverse it?" asked Melissa Hunt, PhD, associate director of clinical training in the Department of Psychology at the University of Pennsylvania in Philadelphia, in an interview withMedscape Medical News.
Dr. Hunt agreed that the imaging findings could be consistent with sexual anhedonia.
"I work with this population a great deal. These women tend to be hypersexual because they are constantly putting themselves in situations where they are re-victimized," she said.
"They often begin to dissociate when someone expresses sexual interest, so what they essentially experience is that they're being raped constantly except that they're never actually saying no."
She added that Dr. Nemeroff's findings of reduced cortical thickness could potentially be useful in measuring treatment response.
Dr. Nemeroff disclosed owning stock, stock options, and equity with CeNeRx, NovaDel Pharma Inc., PharmaNeuroBoost, Revaax Pharma, and Concept Therapeutics. He is on the Board of Directors of the American Foundation for Suicide Prevention (AFSP) and NovaDel Pharma Inc. He is on the Scientific Advisory Boards for CeNeRx, NovaDel Pharma Inc., PharmaNeuroBoost, AFSP, the National Alliance for Research on Schizophrenia and Depression, and Takeda. He holds patents on a device for transdermal delivery of lithium and on a method for assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay. Dr. Hunt has disclosed no relevant financial relationships.
Anxiety Disorders Association of America (ADAA) 32nd Annual Conference. Session 316R, presented April 13, 2012.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n